MGMT Testing in Glioblastomas

Justine Philteos, Brij S. Karmur, Seyed Alireza Mansouri

Research output: Contribution to journalReview article

Abstract

Gliomas, that do not respond to alkylating agent chemotherapy, can be made more sensitive to chemotherapy through promotor mediated epigenetic silencing of the MGMT gene. MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas. Although, MGMT promotor methylation status is becoming more commonly used in neuro-oncology; this test remains imperfect. Because of its increasing use in clinical practice and research, it is integral that we are aware of its pitfalls and complications. Currently, there are many ways to detect a patient's MGMT promotor methylation status, including: quantitative PCR, methylation-specific PCR, pyrosequencing, real time PCR with high resolution melt, and the infinitum methylation EPIC beadChip. The technical aspects, shortcomings, and optimal approach to interpreting the results of each method will be discussed. Furthermore, given that none of these methods have been prospectively validated, the challenge of equivocal cases will be discussed, and technical and logistic strategies for overcoming these challenges will be proposed. Finally, the difficulty in validating these methods, establishing standardized practice, and considerations of the cost of these competing methods will be explored.

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume42
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Glioblastoma
Methylation
Glioma
Drug Therapy
Polymerase Chain Reaction
Alkylating Agents
Traction
Gene Silencing
Epigenomics
Real-Time Polymerase Chain Reaction
Decision Making
Costs and Cost Analysis
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Philteos, Justine ; Karmur, Brij S. ; Mansouri, Seyed Alireza. / MGMT Testing in Glioblastomas. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2019 ; Vol. 42, No. 2. pp. 117-122.
@article{8879bb6e45754cd79f6ab436c0e2da2f,
title = "MGMT Testing in Glioblastomas",
abstract = "Gliomas, that do not respond to alkylating agent chemotherapy, can be made more sensitive to chemotherapy through promotor mediated epigenetic silencing of the MGMT gene. MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas. Although, MGMT promotor methylation status is becoming more commonly used in neuro-oncology; this test remains imperfect. Because of its increasing use in clinical practice and research, it is integral that we are aware of its pitfalls and complications. Currently, there are many ways to detect a patient's MGMT promotor methylation status, including: quantitative PCR, methylation-specific PCR, pyrosequencing, real time PCR with high resolution melt, and the infinitum methylation EPIC beadChip. The technical aspects, shortcomings, and optimal approach to interpreting the results of each method will be discussed. Furthermore, given that none of these methods have been prospectively validated, the challenge of equivocal cases will be discussed, and technical and logistic strategies for overcoming these challenges will be proposed. Finally, the difficulty in validating these methods, establishing standardized practice, and considerations of the cost of these competing methods will be explored.",
author = "Justine Philteos and Karmur, {Brij S.} and Mansouri, {Seyed Alireza}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/COC.0000000000000490",
language = "English (US)",
volume = "42",
pages = "117--122",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

MGMT Testing in Glioblastomas. / Philteos, Justine; Karmur, Brij S.; Mansouri, Seyed Alireza.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 42, No. 2, 01.02.2019, p. 117-122.

Research output: Contribution to journalReview article

TY - JOUR

T1 - MGMT Testing in Glioblastomas

AU - Philteos, Justine

AU - Karmur, Brij S.

AU - Mansouri, Seyed Alireza

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Gliomas, that do not respond to alkylating agent chemotherapy, can be made more sensitive to chemotherapy through promotor mediated epigenetic silencing of the MGMT gene. MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas. Although, MGMT promotor methylation status is becoming more commonly used in neuro-oncology; this test remains imperfect. Because of its increasing use in clinical practice and research, it is integral that we are aware of its pitfalls and complications. Currently, there are many ways to detect a patient's MGMT promotor methylation status, including: quantitative PCR, methylation-specific PCR, pyrosequencing, real time PCR with high resolution melt, and the infinitum methylation EPIC beadChip. The technical aspects, shortcomings, and optimal approach to interpreting the results of each method will be discussed. Furthermore, given that none of these methods have been prospectively validated, the challenge of equivocal cases will be discussed, and technical and logistic strategies for overcoming these challenges will be proposed. Finally, the difficulty in validating these methods, establishing standardized practice, and considerations of the cost of these competing methods will be explored.

AB - Gliomas, that do not respond to alkylating agent chemotherapy, can be made more sensitive to chemotherapy through promotor mediated epigenetic silencing of the MGMT gene. MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker. As such, MGMT is gaining increasing traction in diagnosis, prognostication, and therapeutic decision-making for these highly malignant gliomas. Although, MGMT promotor methylation status is becoming more commonly used in neuro-oncology; this test remains imperfect. Because of its increasing use in clinical practice and research, it is integral that we are aware of its pitfalls and complications. Currently, there are many ways to detect a patient's MGMT promotor methylation status, including: quantitative PCR, methylation-specific PCR, pyrosequencing, real time PCR with high resolution melt, and the infinitum methylation EPIC beadChip. The technical aspects, shortcomings, and optimal approach to interpreting the results of each method will be discussed. Furthermore, given that none of these methods have been prospectively validated, the challenge of equivocal cases will be discussed, and technical and logistic strategies for overcoming these challenges will be proposed. Finally, the difficulty in validating these methods, establishing standardized practice, and considerations of the cost of these competing methods will be explored.

UR - http://www.scopus.com/inward/record.url?scp=85060365435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060365435&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000490

DO - 10.1097/COC.0000000000000490

M3 - Review article

C2 - 30444735

AN - SCOPUS:85060365435

VL - 42

SP - 117

EP - 122

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -